Combined fluorine-18-FDG and carbon-11-methionine PET for diagnosis of tumors in lung and mediastinum.

UNLABELLED We evaluated the value of PET using 18F-fluorodeoxyglucose (FDG) and 11C-methionine, individually or in combination, to distinguish malignant from benign tumors and to identify or exclude mediastinal metastases. METHODS Seventeen patients with a tumor in the lung or mediastinum were evaluated with 18F-FDG and 11C-methionine PET. For morphological comparison, we used CT, and all findings were confirmed by histology of surgical resection specimens (n = 16) or by cytology (n = 1). RESULTS All tumors were visualized equally well with both tracers, and there were no false-positive results. In 2 patients with a malignant tumor, coexisting pneumonia was correctly diagnosed as an inflammatory lesion because of its wedge-like shape. PET correctly excluded hilar invasion and mediastinal lymph node metastases in 10 of 14 patients with primary lung tumor. PET identified mediastinal metastases in 4 of 4 patients. CT failed to detect mediastinal tumor spread in 2 patients and gave a false-positive reading in 2 others. Significantly higher uptake (SUV) and transport rate (slope) values were obtained from malignant than benign lesions with both tracers. No major differences were seen in either the levels of significance or accuracy when the two tracers were compared. Slope values did not add further information to what was obtained with SUV. Density correction of SUV and slope values, to avoid the influence of surrounding air as well as tumor heterogeneity, increased these differences somewhat. Both tracers distinguished malignant from benign lesions with a 93% sensitivity and an accuracy of 89%-95%, but sensitivity improved to 100% when values from both tracers were combined. CONCLUSION Fluorine-18-FDG and 11C-methionine PET visualized all tumors equally well and detected mediastinal spread better than CT. For differentiation purposes, the problems of false-positive and false-negative PET findings could not be safely overcome in a limited number of cases either by the use of both tracers, by the additional use of slope values or by lesion density correction.

[1]  M. Hanson,et al.  Iodine-131-metaiodobenzylguanidine uptake in metastatic carcinoid tumor to the orbit. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[2]  L G Strauss,et al.  The applications of PET in clinical oncology. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  Young Hi Choi,et al.  CT and MR Imaging in Staging Non-Small Cell Bronchogenic Carcinoma , 1995 .

[4]  R. Coleman,et al.  Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. , 1993, Radiology.

[5]  M E Phelps,et al.  Whole-Body Positron Emission Tomography and Fluorodeoxyglucose , 2006 .

[6]  D. Slosman,et al.  Satellite PET and lung cancer: a prospective study in surgical patients , 1993, Nuclear medicine communications.

[7]  N. Gupta,et al.  Positron emission tomography of lung tumors and mediastinal lymph nodes using [18F]fluorodeoxyglucose , 1994 .

[8]  T Jones,et al.  Glucose utilization in vivo by human pulmonary neoplasms , 1987, Cancer.

[9]  K. Ishiwata,et al.  Positron Emission Tomography for Treatment Evaluation and Recurrence Detection Compared with CT in Long-Term Follow-up Cases of Lung Cancer , 1992, Clinical nuclear medicine.

[10]  D A Schenk,et al.  Transbronchial needle aspiration in the diagnosis of bronchogenic carcinoma. , 1987, Chest.

[11]  E H Moore,et al.  Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. , 1992, Radiology.

[12]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[13]  D. Jewett,et al.  Routine production of 2-deoxy-2-[18F]fluoro-D-glucose by direct nucleophilic exchange on a quaternary 4-aminopyridinium resin. , 1990, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[14]  C S Patlak,et al.  Graphical Evaluation of Blood-to-Brain Transfer Constants from Multiple-Time Uptake Data , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[15]  T. Tong,et al.  Cancer statistics, 1994 , 1994, CA: a cancer journal for clinicians.

[16]  E. Buonocore,et al.  Characterization of Chest Masses by FDG Positron Emission Tomography , 1995, Clinical nuclear medicine.

[17]  W. Seed,et al.  Interpretation of negative results in fine needle aspiration of discrete pulmonary lesions. , 1986, Thorax.

[18]  J. Hatazawa,et al.  Clinical assessment of therapeutic effects on cancer using 18F-2-fluoro-2-deoxy-D-glucose and positron emission tomography: preliminary study of lung cancer. , 1990, International journal of radiation oncology, biology, physics.

[19]  S. Kelly,et al.  Percutaneous needle aspiration biopsy of chest lesions. New instrument and new technique. , 1988, Chest.

[20]  R. Wahl,et al.  Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. , 1994, Radiology.

[21]  F. Fazio,et al.  Quantitative Measurement of Regional Extravascular Lung Density Using Positron Emission and Transmission Tomography , 1981, Journal of computer assisted tomography.

[22]  E. Rota Kops,et al.  Performance characteristics of an eight-ring whole body PET scanner. , 1990, Journal of computer assisted tomography.

[23]  R Iwata,et al.  Differential diagnosis of lung tumor with positron emission tomography: a prospective study. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[24]  S Yoshioka,et al.  Lung tumor imaging by positron emission tomography using C-11 L-methionine. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[25]  S J Swensen,et al.  Solitary pulmonary nodule: CT evaluation of enhancement with iodinated contrast material--a preliminary report. , 1992, Radiology.

[26]  M P Frick,et al.  Diagnostic efficacy of PET-FDG imaging in solitary pulmonary nodules. Potential role in evaluation and management. , 1993, Chest.

[27]  O. Brodin,et al.  Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials , 1995 .

[28]  V. Lowe,et al.  Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. , 1994, Radiology.

[29]  G. Jung,et al.  Percutaneous Needle Aspiration Biopsy of Chest Lesions: Effectivenese When Using an 18-Gauge Needle , 1995 .

[30]  J. Hatazawa,et al.  Relationship between histologic type of primary lung cancer and carbon-11-L-methionine uptake with positron emission tomography. , 1989, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[31]  J. Sunderland,et al.  Detection of scalene lymph node metastases from lung cancer. Positron emission tomography. , 1995, Chest.

[32]  Current applications of imaging procedures in the patient with lung cancer. , 1991, International journal of radiation oncology, biology, physics.

[33]  J. Polák,et al.  Percutaneous thin needle biopsy of malignant and nonmalignant thoracic lesions. , 1989, Radiologia diagnostica.

[34]  N. Gupta,et al.  PET-FDG imaging and transthoracic needle lung aspiration biopsy in evaluation of pulmonary lesions. A comparative risk-benefit analysis. , 1995, Chest.

[35]  B J McNeil,et al.  CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. , 1991, Radiology.

[36]  A. Williams,et al.  Transcutaneous needle aspiration of solitary pulmonary masses: how many passes? , 1987, The American review of respiratory disease.